The prospects and predicaments of intravenous rt-PA in childhood ischemic stroke

Research output: Contribution to journalReview articlepeer-review

Abstract

One of the biggest conundrums in acute treatment of childhood arterial ischemic stroke is administration of intravenous recombinant tissue plasminogen activator. Although the benefit of this treatment is well-established in adults, the same effectiveness in children has not been demonstrated. Diversity of underlying causes of ischemic stroke in children and delay and uncertainty in diagnosis are some of the complexities that make intravenous thrombolysis elusive in this population. Physiological, pharmacological and developmental factors may also play roles in variable effect of intravenous recombinant tissue plasminogen activator in children. Current studies are aimed to determine the safety and efficacy of intravenous thrombolysis in carefully-selected children who would benefit the most from this procedure.

Original languageEnglish (US)
Pages (from-to)255-259
Number of pages5
JournalExpert Review of Neurotherapeutics
Volume14
Issue number3
DOIs
StatePublished - Mar 1 2014
Externally publishedYes

Keywords

  • acute stroke
  • ischemic stroke
  • stroke in children
  • thrombolysis
  • tissue plasminogen activator

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The prospects and predicaments of intravenous rt-PA in childhood ischemic stroke'. Together they form a unique fingerprint.

Cite this